TMAI · · 2 min read

ByteTree Q2 2026 Review

ByteTree Q2 2026 Review

Kit and I recorded the ByteTree Quarterly review on Wednesday, looking at the recent events in financial markets, which have been even more eventful than normal.

The signals for a bubble are clear. The momentum factor is at extreme levels, and speculators are borrowing money to participate. While this is happening, many of the best companies offer good value and are being ignored. Experienced investors know which side to take. As the Grail Knight said, “Choose wisely.”

In recent months, we have witnessed a surge in semiconductor demand as Big Tech scrambles to build compute capacity at a record pace. Can they afford it? The market has its doubts. The Iran War was forecast to end, time and again, but when the ceasefire finally came, it proved short-lived. Where is the world getting its oil from? Gold has stumbled but still looks promising. The UK has lost another prime minister, and bond yields are looking stable, which is itself a surprise.

We are delighted to share the full webinar with you today, available on our YouTube channel via the link below. Please do like and subscribe to ensure you see all future content. We will be more active on our YouTube channel going forward.

Please let me know your thoughts by emailing me at charlie.morris@bytetree.com or tweeting me @AtlasPulse.

Many thanks,

Charlie Morris

Editor, The Multi-Asset Investor


Q2 2026 Presentation

P.S. Download the full Q2 2026 presentation below.


The Multi-Asset Investor is issued by ByteTree Asset Management Ltd, an appointed representative of Strata Global which is authorised and regulated by the Financial Conduct Authority. ByteTree Asset Management is a wholly owned subsidiary of ByteTree Group Ltd.

General - Your capital is at risk when you invest, never risk more than you can afford to lose. Past performance and forecasts are not reliable indicators of future results. Bid/offer spreads, commissions, fees and other charges can reduce returns from investments. There is no guarantee dividends will be paid. Overseas shares - Some recommendations may be denominated in a currency other than sterling. The return from these may increase or decrease as a result of currency fluctuations. Any dividends will be taxed at source in the country of issue.

Funds - Fund performance relies on the performance of the underlying investments, and there is counterparty default risk which could result in a loss not represented by the underlying investment. Exchange Traded Funds (ETFs) with derivative exposure (leveraged or inverted ETFs) are highly speculative and are not suitable for risk-averse investors.

Bonds - Investing in bonds carries interest rate risk. A bondholder has committed to receiving a fixed rate of return for a fixed period. If the market interest rate rises from the date of the bond's purchase, the bond's price will fall. There is also the risk that the bond issuer could default on their obligations to pay interest as scheduled, or to repay capital at the maturity of the bond.

Taxation - Profits from investments, and any profits from converting cryptocurrency back into fiat currency is subject to capital gains tax. Tax treatment depends on individual circumstances and may be subject to change.

Investment Director: Charlie Morris. Editors or contributors may have an interest in recommendations. Information and opinions expressed do not necessarily reflect the views of other editors/contributors of ByteTree Group Ltd. ByteTree Asset Management (FRN 933150) is an Appointed Representative of Strata Global Ltd (FRN 563834), which is regulated by the Financial Conduct Authority.

© 2026 ByteTree Group Ltd

Read next

It’s Coming Home
TMAI · The Multi-Asset Investor, TMAI + Quality and Pro tiers

It’s Coming Home

Since 2007, the UK commercial property sector has lagged the market, but there is now a catalyst for deep discounts to be realised.

AI Drives Genomics
TMAI · The Multi-Asset Investor, TMAI + Quality and Pro tiers

AI Drives Genomics

Trade in Whisky; This week I’ll be revisiting biotech and genomics, but before we get there, I will address